home *** CD-ROM | disk | FTP | other *** search
- Document 0424
- DOCN M9620424
- TI Hydroxylated aromatic inhibitors of HIV-1 integrase.
- DT 9602
- AU Burke TR Jr; Fesen MR; Mazumder A; Wang J; Carothers AM; Grunberger D;
- Driscoll J; Kohn K; Pommier Y; Laboratories of Medicinal Chemistry and
- Molecular Pharmacology,; National Cancer Institute, National Institutes
- of Health,; Bethesda, Maryland 20892, USA.
- SO J Med Chem. 1995 Oct 13;38(21):4171-8. Unique Identifier : AIDSLINE
- MED/96028186
- AB Efficient replication of HIV-1 requires integration of a DNA copy of the
- viral genome into a chromosome of the host cell. Integration is
- catalyzed by the viral integrase, and we have previously reported that
- phenolic moieties in compounds such as flavones, caffeic acid phenethyl
- ester (CAPE, 2), and curcumin confer inhibitory activity against HIV-1
- integrase. We now extend these findings by performing a comprehensive
- structure-activity relationship using CAPE analogues. Approximately 30
- compounds have been prepared as HIV integrase inhibitors based on the
- structural lead provided by CAPE, which has previously been shown to
- exhibit an IC50 value of 7 microM in our integration assay. These
- analogues were designed to examine specific features of the parent CAPE
- structure which may be important for activity. Among the features
- examined for their effects on inhibitory potency were ring substitution,
- side chain length and composition, and phenyl ring conformational
- orientation. In an assay which measured the combined effect of two
- sequential steps, dinucleotide cleavage and strand transfer, several
- analogues have IC50 values for 3'-processing and strand transfer lower
- than those of CAPE. Inhibition of strand transfer was assayed using both
- blunt-ended and precleaved DNA substrates. Disintegration using an
- integrase mutant lacking the N-terminal zinc finger and C-terminal
- DNA-binding domains was also inhibited by these analogues, suggesting
- that the binding site for these compounds resides in the central
- catalytic core. Several CAPE analogues were also tested for selective
- activity against transformed cells. Taken together, these results
- suggest that the development of novel antiviral agents for the treatment
- of acquired immune deficiency syndrome can be based upon inhibition of
- HIV-1 integrase.
- DE Animal Antiviral Agents/*CHEMICAL SYNTHESIS Apoptosis/DRUG EFFECTS
- Base Sequence Binding Sites Caffeic Acids/*CHEMISTRY/PHARMACOLOGY
- Cell Line, Transformed DNA/CHEMISTRY/METABOLISM DNA
- Nucleotidyltransferases/*ANTAGONISTS & INHIB Enzyme
- Inhibitors/*CHEMICAL SYNTHESIS Human Hydroxylation HIV/DRUG EFFECTS
- Molecular Conformation Molecular Sequence Data Molecular Structure
- Nuclear Magnetic Resonance Phenylethyl Alcohol/*ANALOGS &
- DERIVATIVES/CHEMISTRY/PHARMACOLOGY Rats Structure-Activity
- Relationship Support, Non-U.S. Gov't Tumor Cells, Cultured Zinc
- Fingers JOURNAL ARTICLE
-
- SOURCE: National Library of Medicine. NOTICE: This material may be
- protected by Copyright Law (Title 17, U.S.Code).
-
-